[1] Hubbell J A, Thomas S N, Swartz M A. Materials engineering for immunomodulation[J]. Nature, 462, 449-460(2009).
[2] Viehl C T, Moore T T, Liyanage U K et al. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice[J]. Annals of Surgical Oncology, 13, 1252-1258(2006).
[3] Gabrilovich D I. Myeloid-derived suppressor cells[J]. Cancer Immunology Research, 5, 3-8(2017).
[4] Dominguez G A, Condamine T, Mony S et al. Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody[J]. Clinical Cancer Research, 23, 2942-2950(2017).
[5] Nishino M, Sholl L M, Hodi F S et al. Anti-PD-1-related pneumonitis during cancer immunotherapy[J]. The New England Journal of Medicine, 373, 288-290(2015).
[6] Michot J M, Bigenwald C, Champiat S et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review[J]. European Journal of Cancer, 54, 139-148(2016).
[7] Hotaling N A, Tang L, Irvine D J et al. Biomaterial strategies for immunomodulation[J]. Annual Review of Biomedical Engineering, 17, 317-349(2015).
[8] Goodwin T J, Shen L M, Hu M Y et al. Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival[J]. Biomaterials, 141, 260-271(2017).
[9] Zou J H, Li L, Yang Z et al. Phototherapy meets immunotherapy: a win-win strategy to fight against cancer[J]. Nanophotonics, 10, 3229-3245(2021).
[10] Mohiuddin T M, Zhang C Y, Sheng W J et al. Near infrared photoimmunotherapy: a review of recent progress and their target molecules for cancer therapy[J]. International Journal of Molecular Sciences, 24, 2655(2023).
[11] Kobayashi H, Choyke P L. Near-infrared photoimmunotherapy of cancer[J]. Accounts of Chemical Research, 52, 2332-2339(2019).
[12] Liu Y M, Zhang L, Chang R et al. Supramolecular cancer photoimmunotherapy based on precise peptide self-assembly design[J]. Chemical Communications, 58, 2247-2258(2022).
[13] Peng Z, Lü X L, Huang S G. Photoimmunotherapy: a new paradigm in solid tumor immunotherapy[J]. Cancer Control, 29, 107327482210888(2022).
[14] Xu X X, Lu H X, Lee R D. Near infrared light triggered photo/immuno-therapy toward cancers[J]. Frontiers in Bioengineering and Biotechnology, 8, 488(2020).
[15] Paraboschi I, Turnock S, Kramer-Marek G et al. Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers: challenges and potentials for human applications[J]. Critical Reviews in Oncology/Hematology, 161, 103325(2021).
[16] Matsuoka K, Yamada M, Sato M et al. Near-infrared photoimmunotherapy for thoracic cancers: a translational perspective[J]. Biomedicines, 10, 1662(2022).
[17] Yamada M, Matsuoka K, Sato M et al. Recent advances in localized immunomodulation technology: application of NIR-PIT toward clinical control of the local immune system[J]. Pharmaceutics, 15, 561(2023).
[18] Mussini A, Uriati E, Bianchini P et al. Targeted photoimmunotherapy for cancer[J]. Biomolecular Concepts, 13, 126-147(2022).
[19] Castano A P, Mroz P, Hamblin M R. Photodynamic therapy and anti-tumour immunity[J]. Nature Reviews: Cancer, 6, 535-545(2006).
[20] Chen Z K, Liu L L, Liang R J et al. Bioinspired hybrid protein oxygen nanocarrier amplified photodynamic therapy for eliciting anti-tumor immunity and abscopal effect[J]. ACS Nano, 12, 8633-8645(2018).
[21] Nagaya T, Friedman J, Maruoka Y et al. Host immunity following near-infrared photoimmunotherapy is enhanced with PD-1 checkpoint blockade to eradicate established antigenic tumors[J]. Cancer Immunology Research, 7, 401-413(2019).
[22] Sano K, Nakajima T, Choyke P L et al. Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors[J]. ACS Nano, 7, 717-724(2013).
[23] Kobayashi H, Choyke P L. Super enhanced permeability and retention (SUPR) effects in tumors following near infrared photoimmunotherapy[J]. Nanoscale, 8, 12504-12509(2016).
[24] Juweid M, Neumann R, Paik C et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier[J]. Cancer Research, 52, 5144-5153(1992).
[25] Wei D F, Qi J X, Hamblin M R et al. Near-infrared photoimmunotherapy: design and potential applications for cancer treatment and beyond[J]. Theranostics, 12, 7108-7131(2022).
[26] Pitt J M, Marabelle A, Eggermont A et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy[J]. Annals of Oncology, 27, 1482-1492(2016).
[27] Maruoka Y, Wakiyama H, Choyke P L et al. Near infrared photoimmunotherapy for cancers: a translational perspective[J]. EBioMedicine, 70, 103501(2021).
[28] Colombo M P, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy[J]. Nature Reviews. Cancer, 7, 880-887(2007).
[29] Sato K, Sato N, Xu B Y et al. Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy[J]. Science Translational Medicine, 8, 352ra110(2016).
[30] Attia P, Maker A V, Haworth L R et al. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma[J]. Journal of Immunotherapy, 28, 582-592(2005).
[31] Onizuka S, Tawara I, Shimizu J et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody[J]. Cancer Research, 59, 3128-3133(1999).
[32] Okada R, Maruoka Y, Furusawa A et al. The effect of antibody fragments on CD25 targeted regulatory T cell near-infrared photoimmunotherapy[J]. Bioconjugate Chemistry, 30, 2624-2633(2019).
[33] Okada R, Kato T, Furusawa A et al. Local depletion of immune checkpoint ligand CTLA4 expressing cells in tumor beds enhances antitumor host immunity[J]. Advanced Therapeutics, 4, 2000269(2021).
[34] Vijayan D, Young A, Teng M W L et al. Targeting immunosuppressive adenosine in cancer[J]. Nature Reviews. Cancer, 17, 709-724(2017).
[35] Xue G, Wang Z Y, Zheng N B et al. Elimination of acquired resistance to PD-1 blockade via the concurrent depletion of tumour cells and immunosuppressive cells[J]. Nature Biomedical Engineering, 5, 1306-1319(2021).
[36] Yuan L, Tatineni J, Mahoney K M et al. VISTA: a mediator of quiescence and a promising target in cancer immunotherapy[J]. Trends in Immunology, 42, 209-227(2021).
[37] Wakiyama H, Furusawa A, Okada R et al. Opening up new VISTAs: V-domain immunoglobulin suppressor of T cell activation (VISTA) targeted near-infrared photoimmunotherapy (NIR-PIT) for enhancing host immunity against cancers[J]. Cancer Immunology, 71, 2869-2879(2022).
[38] Kobayashi H, Furusawa A, Rosenberg A et al. Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity[J]. International Immunology, 33, 7-15(2021).
[39] Hanaoka H, Nakajima T, Sato K et al. Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel[J]. Nanomedicine, 10, 1139-1147(2015).
[40] Mao C Q, Li F, Zhao Y et al. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment[J]. Theranostics, 8, 6274-6290(2018).
[41] Tang Q G, Nagaya T, Liu Y et al. Real-time monitoring of microdistribution of antibody-photon absorber conjugates during photoimmunotherapy in vivo[J]. Journal of Controlled Release, 260, 154-163(2017).
[42] Tang Q G, Nagaya T, Liu Y et al. 3D mesoscopic fluorescence tomography for imaging micro-distribution of antibody-photon absorber conjugates during near infrared photoimmunotherapy in vivo[J]. Journal of Controlled Release, 279, 171-180(2018).
[44] Katsube R, Noma K, Ohara T et al. Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer[J]. Scientific Reports, 11, 1693(2021).
[45] Watanabe S, Noma K, Ohara T et al. Photoimmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma[J]. Cancer Biology & Therapy, 20, 1234-1248(2019).
[46] Bieniasz-Krzywiec P, Martín-Pérez R, Ehling M et al. Podoplanin-expressing macrophages promote lymphangiogenesis and lymphoinvasion in breast cancer[J]. Cell Metabolism, 30, 917-936(2019).
[47] Jaynes J M, Sable R, Ronzetti M et al. Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses[J]. Science Translational Medicine, 12, eaax6337(2020).
[48] Nishimura T, Mitsunaga M, Ito K et al. Cancer neovasculature-targeted near-infrared photoimmunotherapy (NIR-PIT) for gastric cancer: different mechanisms of phototoxicity compared to cell membrane-targeted NIR-PIT[J]. Gastric Cancer, 23, 82-94(2020).
[49] Shi Q X, Tao Z, Yang H et al. PDGFRβ-specific affibody-directed delivery of a photosensitizer, IR700, is efficient for vascular-targeted photodynamic therapy of colorectal cancer[J]. Drug Delivery, 24, 1818-1830(2017).
[50] Li F, Zhao Y, Mao C Q et al. RGD-modified albumin nanoconjugates for targeted delivery of a porphyrin photosensitizer[J]. Molecular Pharmaceutics, 14, 2793-2804(2017).
[51] Dou X B, Nomoto T, Takemoto H et al. Effect of multiple cyclic RGD peptides on tumor accumulation and intratumoral distribution of IRDye 700DX-conjugated polymers[J]. Scientific Reports, 8, 8126(2018).
[52] Zhao Y, Li F, Mao C Q et al. Multiarm nanoconjugates for cancer cell-targeted delivery of photosensitizers[J]. Molecular Pharmaceutics, 15, 2559-2569(2018).
[53] Kato T, Furusawa A, Okada R et al. Near-infrared photoimmunotherapy targeting podoplanin-expressing cancer cells and cancer-associated fibroblasts[J]. Molecular Cancer Therapeutics, 22, 75-88(2023).
[54] Nentwig K, Unterhuber T, Wolff K D et al. The impact of intraoperative frozen section analysis on final resection margin status, recurrence, and patient outcome with oral squamous cell carcinoma[J]. Clinical Oral Investigations, 25, 6769-6777(2021).
[55] Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy[J]. Cancer Research, 74, 2907-2912(2014).
[56] Bao R, Wang Y P, Lai J H et al. Enhancing anti-PD-1/PD-L1 immune checkpoint inhibitory cancer therapy by CD276-targeted photodynamic ablation of tumor cells and tumor vasculature[J]. Molecular Pharmaceutics, 16, 339-348(2019).
[57] Ito K, Mitsunaga M, Arihiro S et al. Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms[J]. BMC Cancer, 16, 37(2016).
[58] Read E D, Eu P, Little P J et al. The status of radioimmunotherapy in CD20+ non-Hodgkin’s lymphoma[J]. Targeted Oncology, 10, 15-26(2015).
[59] Loeffler M, Krüger J A, Niethammer A G et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake[J]. The Journal of Clinical Investigation, 116, 1955-1962(2006).
[60] Xia C L, Yin S H, To K K W et al. CD39/CD73/A2AR pathway and cancer immunotherapy[J]. Molecular Cancer, 22, 44(2023).
[61] Cognetti D M, Johnson J M, Curry J M et al. Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma[J]. Head & Neck, 43, 3875-3887(2021).
[62] Tahara M, Okano S, Enokida T et al. A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma[J]. International Journal of Clinical Oncology, 26, 1812-1821(2021).
[63] Gomes-da-Silva L C, Kepp O, Kroemer G. Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death[J]. Oncoimmunology, 9, 1841393(2020).
[64] Zhang X Y, Nakajima T, Mizoi K et al. Imaging modalities for monitoring acute therapeutic effects after near-infrared photoimmunotherapy in vivo[J]. Journal of Biophotonics, 15, e202100266(2022).
[65] Sato K, Ando K, Okuyama S et al. Photoinduced ligand release from a silicon phthalocyanine dye conjugated with monoclonal antibodies: a mechanism of cancer cell cytotoxicity after near-infrared photoimmunotherapy[J]. ACS Central Science, 4, 1559-1569(2018).
[66] Matsuoka K, Yamada M, Fukatsu N et al. Contrast-enhanced ultrasound imaging for monitoring the efficacy of near-infrared photoimmunotherapy[J]. eBioMedicine, 95, 104737(2023).
[67] Sano K, Mitsunaga M, Nakajima T et al. Acute cytotoxic effects of photoimmunotherapy assessed by 18F-FDG PET[J]. Journal of Nuclear Medicine, 54, 770-775(2013).
[68] Nakajima T, Sano K, Mitsunaga M et al. Real-time monitoring of in vivo acute necrotic cancer cell death induced by near infrared photoimmunotherapy using fluorescence lifetime imaging[J]. Cancer Research, 72, 4622-4628(2012).
[69] Maruoka Y, Nagaya T, Nakamura Y et al. Evaluation of early therapeutic effects after near-infrared photoimmunotherapy (NIR-PIT) using luciferase-luciferin photon-counting and fluorescence imaging[J]. Molecular Pharmaceutics, 14, 4628-4635(2017).
[70] Liang C P, Nakajima T, Watanabe R et al. Real-time monitoring of hemodynamic changes in tumor vessels during photoimmunotherapy using optical coherence tomography[J]. Journal of Biomedical Optics, 19, 98004(2014).
[71] Kishimoto S, Oshima N, Yamamoto K et al. Molecular imaging of tumor photoimmunotherapy: evidence of photosensitized tumor necrosis and hemodynamic changes[J]. Free Radical Biology and Medicine, 116, 1-10(2018).
[72] Shirasu N, Shibaguchi H, Yamada H et al. Highly versatile cancer photoimmunotherapy using photosensitizer-conjugated avidin and biotin-conjugated targeting antibodies[J]. Cancer Cell International, 19, 299(2019).
[73] Mitsunaga M, Nakajima T, Sano K et al. Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate[J]. Bioconjugate Chemistry, 23, 604-609(2012).
[74] Nakajima T, Sano K, Choyke P L et al. Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model[J]. Theranostics, 3, 357-365(2013).
